Update on pharmacotherapy for pulmonary hypertension

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) is a rare, progressive condition with significant mortality.
• Treatment options for PAH have expanded considerably in the last decade.
• Therapies target key signaling pathways including nitric oxide, endothelin, and prostacyclin.

Purpose of the Study:

• To review the advancements in pharmacological treatments for pulmonary arterial hypertension.
• To highlight the impact of new therapies on patient outcomes and disease management.
• To emphasize the importance of specialized centers in PAH treatment.

Main Methods:

• Review of current pharmacological treatments for PAH.
• Analysis of drug efficacy targeting nitric oxide, endothelin, and prostacyclin pathways.
• Inclusion of novel oral agents and combination therapies.

Main Results:

• Specialized center treatment has improved patient symptoms, exercise capacity, and reduced mortality.
• New oral drugs like macitentan, riociguat, and selexipag show significant benefits.
• Combination therapies are demonstrating positive effects in managing PAH.

Conclusions:

• Pharmacological advancements have substantially improved PAH prognosis.
• Emerging therapies and combination strategies are poised to transform future PAH treatment.
• Recognition of treatable forms like chronic thromboembolic pulmonary hypertension is crucial.